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AbstrAct
Objectives Opioid- induced constipation (OIC) 
can affect up to 63% of all patients with cancer. 
The objectives of this study were to assess quality 
of life as well as efficacy and safety of naloxegol, 
in patients with cancer with OIC.
Methods An observational study was made 
of a cohort of patients with cancer and with 
OIC exhibiting an inadequate response to 
laxatives and treated with naloxegol. The 
sample consisted of adult outpatients with a 
Karnofsky performance status score ≥50. The 
Patient Assessment of Constipation Quality of 
Life Questionnaire (PAC- QOL) and the Patient 
Assessment of Constipation Symptoms (PAC- 
SYM) were applied for 3 months.
results A total of 126 patients (58.2% males) 
with a mean age of 61.3 years (range 34–89) 
were included. Clinically relevant improvements 
(>0.5 points) were recorded in the PAC- QOL and 
PAC- SYM questionnaires (p<0.0001) from 15 
days of treatment. The number of days a week 
with complete spontaneous bowel movements 
increased significantly (p<0.0001) from 2.4 to 
4.6 on day 15, 4.7 after 1 month and 5 after 
3 months. Pain control significantly improved 
(p<0.0001) during follow- up. A total of 13.5% 
of the patients (17/126) presented some 
gastrointestinal adverse reaction, mostly of mild 
(62.5%) or moderate intensity (25%).
conclusions Clinically relevant improvements 
in OIC- related quality of life, number of bowel 
movements and constipation- related symptoms 
were recorded as early as after 15 days of 
treatment with naloxegol in patients with cancer 
and OIC, with a good safety profile.
IntrOductIOn
Opioid- induced constipation (OIC) is 
one of the most common adverse effects 
of opioid use for the treatment of pain, 
affecting 15%–90% of all non- cancer 
patients and up to 63% of all patients 
with cancer.1–10
OIC may occur at the start of opioid 
use and persist throughout the treatment 
period, in contrast to other adverse effects 
of opioids such as nausea, vomiting and 
sedation, which disappear over time.5 
Treatment based on hygiene- dietary 
measures and laxatives is not effective 
in many patients. The discontinuation of 
opioid therapy is the only option in such 
cases.11 In up to one- third of all cases, 
the opioid dose is reduced by the physi-
cian or by the patient in the hope that this 
will cause the symptom to disappear.10 
However, it has been shown that the dose 
at which constipation usually occurs is 
approximately four times lower than the 
dose required to produce an analgesic 
effect; dose reduction is therefore unlikely 
to cause constipation to disappear.12
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Constipation has a negative impact on patient general 
condition and quality of life, often leading to tempo-
rary discontinuation of opioid treatment, resulting in 
inadequate pain control.10
For patients, constipation relief may be even more 
important than pain relief.13 14 Chronic opioid use 
causes constipation to also become chronic, with the 
resulting risk of haemorrhoids, rectal fissures, bowel 
obstruction that may lead to colon rupture and, in 
extreme cases, death.6
No medical definition of OIC had been established 
before presentation of the Rome IV criteria,15 16 where 
OIC appeared as a new category.
The management of constipation includes its 
prevention, the suppression of causal factors and the 
use of laxatives.17 In patients with cancer, the Spanish 
Society of Medical Oncology (Sociedad Española de 
Oncología Médica) guidelines recommend continued 
laxative use together with opioid treatment.18 The 
European Society for Medical Oncology has recently 
published a guide for the management of constipation 
in patients with cancer.19
The American Gastroenterological Association has 
also recently published guidelines for the manage-
ment of OIC.20 This same year, an European experts 
consensus document has been published on the phys-
iopathology and management of OIC, recommending 
treatment with naloxegol in patients exhibiting an 
inadequate response to laxatives.21
Naloxegol is a pegylated naloxone derivative that 
was approved by the United States Food and Drug 
Administration (FDA) in 2014 for the treatment of 
OIC in adult patients with non- cancer pain, and by 
the European Medicines Agency (EMA) that same year 
for use in patients with or without cancer. The drug is 
indicated for the treatment of OIC in adults with an 
inadequate response to laxatives.
The objective of this study was to assess the evolu-
tion of quality of life and symptoms related to OIC 
in patients with cancer treated with naloxegol, and to 
obtain data on the safety and efficacy of the drug in 
real- life setting.
MethOds
A prospective, observational follow- up study with a 
total duration of 12 months was designed. This report 
presents the results of the interim analysis of the first 
3 months of follow- up in four visits (baseline, 15 days, 
1 month, 3 months).
A total of 16 investigators belonging to centres in 
12 Spanish provinces participated in the study: 12 
medical oncologists, 2 radiation oncologists and 2 
from the Palliative Care Unit.
The first patient was enrolled on 21 September 2017 
and database closure for the interim analysis on 9 April 
2019.
Written informed consent was obtained from all 
patients included in the study.
Patient screening
The study population consisted of patients with cancer 
presenting a confirmed diagnosis of OIC with inad-
equate response to laxatives, and in which treatment 
with naloxegol was indicated.
OIC was defined based on the Rome IV criteria.15 16 
An inadequate response to laxatives was defined as 
patients reporting symptoms of OIC for at least 4 days 
in the 2 weeks prior to the study while receiving treat-
ment with at least one class of laxatives.
The inclusion criteria were: (1) men and women 
over 18 years of age; (2) a diagnosis of active onco-
logical disease requiring treatment with opioids for 
pain control; (3) patients with symptoms of OIC at 
the time of screening (an average of <3 spontaneous 
bowel movements a week with associated symptoms 
of constipation in at least 25% of the bowel move-
ments); (4) patients with an inadequate response to 
laxatives for the treatment of OIC, and with indication 
for naloxegol; (5) patients with a Karnofsky perfor-
mance status score ≥50 at study entry; (6) outpatients 
at study entry; (7) patients with sufficient capacity to 
complete the data corresponding to the symptoms and 
quality of life scales; and (8) patient's signed informed 
consent.
The exclusion criteria were those described as contra-
indication in the Summary of Product Characteristics 
of naloxegol and patients with cognitive impairment 
or uncooperative.
The patients completed a diary recording the number 
of weekly bowel movements, the use of rescue medica-
tion, changes in pain treatments and the appearance of 
adverse reactions to naloxegol.
Primary endpoint
The primary endpoint was the assessment of 
constipation- related quality of life in the patients 
receiving naloxegol, using the Patient Assessment of 
Constipation Quality of Life Questionnaire (PAC- 
QOL), in its validated Spanish version.
The PAC- QOL questionnaire consists of 28 ques-
tions grouped into four subscales: worries and 
concerns, physical discomfort, psychosocial discomfort 
and satisfaction. The patients reported the severity of 
each symptom on a 0–4 point scale referred to the last 
2 weeks. The total score and the score corresponding 
to each subscale were calculated by averaging the 
scores. Changes in the total or subscale scores of ≥0.5 
points were considered clinically relevant. A higher 
PAC- QOL score means poorer quality of life.22
secondary endpoints
The secondary endpoints included evaluation of the 
efficacy of naloxegol in treating OIC over follow- up, 
defined as the proportion of responders: patients with 
three or more bowel movements a week, and one 
or more bowel movements a week additional to the 
number of bowel movements at baseline.
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Table 1 Sociodemographic and clinical data of the patients
% (n) or mean (95% CI)
Age (n=122) 61.3
(95% CI 59.1 to 63.4)
Sex (n=122)
  Male 58.2 (71)
  Female 41.8 (51)
Race (n=121)
  Caucasian 99.2 (120)
  Black 0.8 (1)
Socioeconomic level (n=121)
  Low 18.3 (21)
  Middle 69.6 (80)
  High 12.2 (14)
Body mass index (BMI), kg/m2 (n=118) 24.9 (24.1 to 25.6)
Classification according to BMI (n=118)
  Cachexia (<20 kg/m2) 11 (13)
  Normal (≥20 to <25 kg/m2) 39.8 (47)
  Overweight (≥25 to <30 kg/m2) 38.1 (45)
  Obese (≥30 kg/m2) 11 (13)
Karnofsky performance status (n=122) 77.1
(95% CI 74.9 to 79.3)
Organ affected by the cancer (n=123)
  Lung 35.7 (45)
  Breast 15.1 (19)
  Gastrointestinal 11.1 (14)
  Prostate 8.7 (11)
  Others 27 (34)
Time from cancer diagnosis (n=111) 21.3 months
(95% CI 16.8 to 25.9)
Presence of metastases (n=110) 75.5 (83)
As secondary efficacy endpoint, we evaluated the 
constipation symptoms using the Patient Assessment 
of Constipation Symptoms (PAC- SYM) in its validated 
Spanish version, referred to the last 2 weeks.23 This 
instrument consists of 12 questions with 3 subscales 
(stool, rectal and abdominal symptoms). The patients 
reported the severity of each symptom on a 0–4 point 
scale where 4 corresponds to greatest intensity. The 
total score was calculated from the average of the 
scores of each subscale.
The safety of naloxegol treatment was assessed based 
on the adverse reactions described during patient 
follow- up.
control variables
Information was collected on patient age, gender, 
weight, height, body mass index, socioeconomic 
level (low: annual income in euros<25 000; middle: 
25 000–45 000; high: >45 000), medical history, date 
of cancer diagnosis, organ affected by the cancer, pres-
ence of metastasis, history of treatments for OIC and 
pain control and Karnofsky performance status at 
study entry.
At each visit, the patients scored their pain intensity 
on a 10 cm Visual Analogue Scale (VAS; 0=no pain and 
10=maximum pain).
Mean stool consistency was documented using the 
7- point Bristol scale.24
sample size calculation
Changes in the primary efficacy endpoint, total PAC- 
QOL score, of 0.5 points from baseline or between 
periods were considered clinically significant.22
A sample of 126 patients was estimated to afford 
a statistical power of 99.9% in detecting differences 
of 0.5 points in the PAC- QOL, with a precision of 
±0.03 points in the 95% CI of the differences between 
means, in paired comparisons between periods, with a 
two- tailed alpha significance criterion of 0.05 (Sample 
Power, SPSS).
statistical analysis
A descriptive analysis was made of frequencies and 
percentages for the qualitative variables, with calcu-
lation of the mean, SD and 95% CI, for quantitative 
variables.
Comparisons between variables were made using the 
Fisher exact test or the χ2 test in the case of qualitative 
variables and using the Student’s t- test for the compar-
ison of independent groups if quantitative variables.
Monitoring of the quantitative variables over 
time was based on analysis of variance for repeated 
measures, applying Bonferroni or Games Howell 
corrections according to the homogeneity of variances 
for the control of multiple comparisons. Statistical 
significance was considered for p<0.05. The IBM- 
SPSS V.25.0 statistical package was used throughout. 
The Strengthening the Reporting of Observational 
Studies in Epidemiology guidelines for the presentation 
of information from cohort studies were followed.25
results
A total of 126 patients were included. Ninety- five 
patients completed the 3 months of follow- up. Three 
patients discontinued the study due to physician deci-
sion; 10 discontinued the study due to patient deci-
sion; 1 patient was lost to follow- up; and 17 patients 
had died because of their oncological disease.
clinical history and sociodemographic data
Table 1 shows the characteristics of the patients. 
Seventy- seven patients (61.1%) were receiving treat-
ment for some comorbid condition.
The main cause of the pain was the cancer (91.6%; 
n=109). Opioids that potentially trigger OIC at the 
moment of inclusion were fentanyl in 58.7% of the 
patients (n=74), morphine in 26.2% (n=33), oxyco-
done in 11.9% (n=15) and tapentadol in 2.4% (n=3). 
The pain treatment had been administered for an 
average of 6.2 months before patient inclusion in the 
study (95% CI 4.9 to 7.5).
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Figure 1 Mean number complete spontaneous bowel 
movements per week.
A total of 31.5% of the patients (n=34) had a prior 
history of constipation. The mean duration of OIC 
was 3.8 months (95% CI 2.5 to 5.1), with a median of 
1.4 months.
treatments
The treatments prescribed for the management of OIC 
from its diagnosis to inclusion in the study were: lact-
ulose (58), macrogol (58), enema (10), bisacodyl (13), 
paraffin oil (8), magnesia (5), sennosides (4), fibre (2), 
sodium picosulfate (2), lactitol (1) and psyllium(1).
The naloxegol starting dose was 25 mg/day in 86.7% 
(n=85) and 12.5 mg/day in 12.2% (n=12), while one 
patient received 6.75 mg/day.
During the study, 63.2% of the patients (n=43) 
received concomitant treatment with laxatives (28 
unavailable data at database closure).
At baseline, 63.2% of the patients (n=74) were 
receiving chemotherapy and 85.2% (n=98) were 
receiving treatment with other drugs that could cause 
constipation.
evolution of symptoms
A statistically significant increase in the mean number 
of days a week with complete spontaneous bowel 
movements from baseline (p<0.0001) was observed 
over all the study visits (figure 1).
The Bristol score improved significantly over time 
versus baseline (p<0.0001) from 2 at baseline to 4 on 
day 15 and the subsequent visits.
There was a significant decrease in pain intensity 
between baseline and the next visits (p=0.002 on day 
15 and p<0.0001 at 1 month and 3 months), with a 
VAS score of 4.8 at baseline, 3.6 after 15 days, 3.1 
after 1 month and 3.2 after 3 months.
response to treatment
A total of 82.5% of the patients (n=85) responded to 
treatment with naloxegol after 15 days, 83.2% after 
1 month (n=79) and 87.7% after 3 months (n=64).
The response after 3 months was analysed according 
to whether the patients received concomitant laxative 
therapy, and the dose of naloxegol administered. In 
those patients who did not receive laxatives during the 
study, the 3- month response rate was 88% (n=22): 
75% (n=3) with the 12.5 mg naloxegol dose and 
90.5% (n=19) with the 25 mg dose. In those patients 
who received laxatives in combination with naloxegol, 
the 3- month response rate was 88.4% (n=38): 83.3% 
(n=5) with the 12.5 mg naloxegol dose and 89.2% 
(n=33) with the 25 mg dose. There were no differ-
ences in response to treatment according to the organ 
affected by the cancer.
constipation-related quality of life, evolution of the PAc-
QOl score
Clinically and statistically significant improvement 
(p<0.001) was observed in the PAC- QOL scores from 
baseline and between all the subsequent visits (n=58; 
figure 2). The proportion of patients with clinically 
relevant improvement in the total PAC- QOL score 
was 63% (n=58) after 15 days, 72.9% (n=62) after 
1 month and 75.8% (n=47) after 3 months.
constipation-related symptoms, evolution of the PAc-sYM 
score
Clinically and statistically significant improvement 
(p<0.001) was observed in the PAC- SYM scores from 
baseline and between all the subsequent visits (n=58; 
figure 3). The proportion of patients with clinically 
relevant improvement in the total PAC- SYM score 
was 64.5% (n=60) after 15 days, 76.5% (n=65) after 
1 month and 84.1% (n=53) after 3 months.
Adverse reactions to naloxegol
Seventeen patients (13.5%) experienced some adverse 
reaction to naloxegol, mostly of a gastrointestinal 
nature. Table 2 describes the 24 adverse reactions 
observed. A total of 62.5% (n=15) were mild, 25% 
(n=6) moderate and 8.3% (n=2) severe. Six patients 
required treatment discontinuation and withdrawal 
from the study due to two severe, four moderate and 
two mild adverse reactions. During the first 3 months 
of follow- up, 17 patients died from causes related to 
their malignant disease.
dIscussIOn
The present study evaluates patient quality of life and 
the efficacy and safety of the treatment of OIC with 
naloxegol under real- life conditions. This is the first 
study in patients with cancer and OIC treated with 
naloxegol, since to date only data from case reports 
have been available.26–28 We observed statistically 
significant improvement of OIC- related quality of 
life assessed using the specific PAC- QOL question-
naire, and such improvement was noted from as early 
as 15 days after the start of treatment (p<0.001) and 
persisted during the 3 months of follow- up.
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Figure 2 (A) Evolution of total Patient Assessment of Constipation Quality of Life Questionnaire (PAC- QOL) score from baseline to 
3 months of follow- up (p<0.0001). (B) Mean differences (3 months- baseline) in total score and in the scores of each subscale of the 
PAC- QOL. Differences>0.5 points are considered clinically relevant.
Figure 3 (A) Evolution of total Patient Assessment of Constipation Symptoms (PAC- SYM) score from baseline to 3 months of 
follow- up (p<0.0001). (B) Mean differences (3 months—baseline) in total score and in the scores of each subscale of the PAC- SYM. 
Differences>0.5 points are considered clinically relevant.
Improvement was clinically relevant in 63% of the 
patients after 15 days and in 75.4% after 3 months of 
follow- up. This significant improvement in OIC- related 
quality of life was evidenced in all the subscales of the 
PAC- QOL and in its total score. Improvement in patient 
satisfaction was also notorious, being threefold greater 
than improvement in the other subscales (figure 2).
Clinical symptoms efficacy assessed by the PAC- SYM 
questionnaire also yielded statistically significant find-
ings (p<0.001) referred to both the total score and the 
scores of the three subscales (figure 3). The propor-
tion of patients with clinically relevant improvement 
being 64.5% after 15 days and 84.1% after 3 months. 
In addition, the mean number of days a week with 
complete spontaneous bowel movements increased over 
follow- up and proved significant from as early as day 
15 of treatment (figure 1). Stool consistency as rated by 
the Bristol score also improved. The treatment response 
rate was very high from 15 days (82.5%) and increased 
to 87.7% at the end of the 3- month follow- up period. 
This response could be observed before day 15 in most 
patients, but no visits were scheduled between base-
line and day 15 of treatment, so no firm conclusions 
therefore can be drawn. The treatment afforded rapid 
improvement of patient quality of life and probably 
resulted in fewer physician and emergency room visits. 
And, although there are not enough data to conclude 
that the reduction is associated with naloxegol treat-
ment, it was observed that pain was significantly reduced 
throughout follow- up, thus suggesting a possible rela-
tion. With this, naloxegol offers a solution to OIC, one 
of the main problems associated with opioid therapy. 
Regarding this, naloxegol demonstrated in previous 
studies, similar efficacy in treating OIC independently of 
maintenance opioid type, dose or duration of opioid use 
at baseline, although these data have not been explored 
in our analysis.29–31
The efficacy of naloxegol was evaluated in two pivotal 
phase III trials (Kodiac 4 and Kodiac 5), both of which 
were double- blind, placebo- controlled, two- parallel 
group multicentre studies with two naloxegol doses 
(12.5 mg and 25 mg). Concomitant laxative use was not 
permitted during naloxegol treatment. A total of 1325 
patients with non- cancer pain and OIC were included. 
The duration of the treatment period was 12 weeks in 
both studies. In the pooled analysis of these trials, patients 
without an inadequate response to laxatives represented 
54%. It was observed a significantly higher responder 
rate among the patients with an inadequate response to 
laxatives than in the placebo group (p<0.01), with both 
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Table 2 Adverse reactions to naloxegol observed during the 
study
% (n)
Patients with adverse reaction 13.5 (17)
Adverse reactions
  Abdominal pain 9.5 (12)
  Abdominal bloating 4 (5)
  Diarrhoea 3.2 (4)
  Nausea 1.6 (2)
  Dysaesthesia 10.8 (1)
drug doses. The response rate after 12 weeks was 42.5% 
for the 12.5 mg dose (n=240) and 47.7% (n=241) for 
the patients receiving 25 mg of naloxegol.31 32
In our study, the treatment response rate was 75% 
(n=3) among the patients receiving 12.5 mg and 90.5% 
(n=19) in those administered 25 mg of naloxegol, in the 
absence of concomitant laxative treatment, the latter 
being a study inclusion criterion in clinical trials.31 32 
Our results should be interpreted with caution, since the 
reported data are per protocol, the number of patients 
particularly in the lower naloxegol dose group was small 
and no patient control group was included. The findings 
therefore may be overestimated.
In the clinical trials with naloxegol, significant differ-
ences were only found in the PAC- QOL patient satis-
faction subscale compared with placebo at 12 weeks 
versus baseline. There were no significant differences 
in the other subscales.32 No control group was available 
in our observational study to compare the improve-
ments, which proved significant for all the questionnaire 
subscales.
The safety of naloxegol was mainly evaluated in four 
phase III trials, one of which lasted 52 weeks.33 The dura-
tion of the placebo- controlled trials was 12 weeks—this 
being a requirement of the EMA for studies of constipa-
tion.34 A higher incidence of adverse effects was reported 
in the group administered the 25 mg dose—the most 
common problems being gastrointestinal disorders, with 
a frequency of >5% (abdominal pain, diarrhoea, nausea, 
flatulence). These adverse effects occurred mainly in the 
first 7 days of treatment. The safety profile observed in 
our study is consistent with the safety description of the 
drug.
Our study has limitations inherent to its observational 
design under conditions of standard clinical practice. 
There was no control group, and the reported data were 
evaluated per protocol and are the result of an interim 
analysis. The findings therefore may be overestimated. 
It is also important to notice that, based in the general 
clinical practice, most patients were receiving fentanyl 
(58.7%) for pain treatment at baseline. However, it has 
been shown that the efficacy of naloxegol is not depen-
dent on the type of opioid used,29–31 suggesting that these 
results could be extrapolated to other opioid treatments 
and administration routes. The subjects included in the 
study were patients with cancer, of which 63.2% were 
receiving chemotherapy and 85.2% were being treated 
with other drugs that could cause constipation. The 
clinical trials with naloxegol were conducted in patients 
without cancer, and the inclusion of patients with treat-
ments that could cause constipation was limited. In this 
regard, a poorer response to treatment than seen in the 
clinical trials could have been expected, but this was not 
the case.
Based on the results obtained, it can be concluded that 
naloxegol as treatment for OIC in patients with cancer 
with an inadequate response to laxatives was more effec-
tive than expected. These findings should be confirmed 
in the context of a randomised clinical trial.
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